Skip to main content
Equibles
CNMD logo

CNMD · CONMED Corp · Metrics

Track CNMD — free

Use CNMD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CNMD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$46.30 +0.08 (+0.17%) At close · Sep 11
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$1.39B
Shares
29.95M

CNMD metrics

86 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$46.30
Market cap
$1.39B

Price action

20 metrics
Price change (1W)
-6.1%
Price change (30D)
-8.2%
Price change (3M)
+33.2%
Price change (6M)
+24.2%
Price change (YTD)
+14.0%
Price change (1Y)
-14.3%
Trailing year
Price change (5Y)
-62.3%
52-week high
$54.05
52-week low
$32.11
Change from 52-week high
-14.3%
Change from 52-week low
+44.2%
Annualized volatility
45.4%
Annualized volatility (3M)
56.4%
Beta
1.0
RSI (14D)
40.3
Price vs SMA 50
+0.6%
Price vs SMA 200
+14.0%
Avg volume (3M)
564,054
Relative volume
0.4
Average dollar volume
$23.64M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
29.95M

Valuation

12 metrics
P / E (TTM)
24.5
Trailing earnings · reciprocal yield 4.1%
PEG ratio
2.1
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.0×
reciprocal yield 98.9%
P / book
1.3
reciprocal yield 75.1%
FCF yield
9.7%
TTM · current market cap
Buyback yield
0.0%
P / FCF
10.3
reciprocal yield 9.7%
P / operating cash flow
9.2
reciprocal yield 10.9%
Earnings yield
4.1%

Historical valuation

8 metrics
P / E historical average (3Y)
21.5×
reciprocal yield 4.6%
P / E historical average (5Y)
87.4×
reciprocal yield 1.1%
EV / revenue historical average (3Y)
2.1×
reciprocal yield 46.6%
EV / revenue historical average (5Y)
3.1×
reciprocal yield 32.4%
EV / EBIT historical average (3Y)
21.7×
reciprocal yield 4.6%
EV / EBIT historical average (5Y)
34.9×
reciprocal yield 2.9%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
0.4%
Trailing 12 months
Payout ratio
21.9%
Shareholder yield
—
Dividend / share (TTM)
$0.20
Dividend growth YoY
-75.0%
Dividend growth streak
—
Last ex-dividend
2025-09-15

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-29

Profitability

9 metrics
Gross margin
55.8%
Operating margin
8.0%
Trailing 12 months
Net margin
4.1%
Gross profit (TTM)
$765.31M
Operating profit (TTM)
$110.32M
Net income (TTM)
$56.50M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
9.8%
Effective tax rate
32.1%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+0.3%
Year over year
Net income growth YoY
+7.7%
Revenue (TTM)
$1.37B
Trailing 12 months
EPS growth YoY
+11.6%
Shares change YoY
-3.0%
Year over year · fewer shares
Revenue CAGR (3Y)
+9.6%
Revenue CAGR (5Y)
+9.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
+36.4%
FCF CAGR (3Y)
+135.3%
FCF CAGR (5Y)
+24.0%

Quality

14 metrics
Return on equity
5.4%
Return on assets
2.5%
Debt / equity
—
Current ratio
1.5
EBITDA (TTM)
—
Free cash flow (TTM)
$134.46M
Quick ratio
0.7
Interest coverage
3.7
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$37.33M
Total assets
$2.30B
Total debt
$794.17M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$150.59M
Capital expenditures (TTM)
$16.12M
R&D (TTM)
$60.63M
SG&A (TTM)
$594.35M
Stock compensation (TTM)
$20.29M
R&D / revenue
4.4%
Stock compensation / revenue
1.5%

Ownership (13F)

3 metrics
13F filers
246
13F filer change QoQ
+8
Institutional ownership
114.0%

Short interest

3 metrics
Short interest
7.6%
Latest settlement · 7.2 days to cover
Days to cover
7.2d
Short-squeeze score
66 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 816956 CUSIP 207410101 13F (30d) 66 filings 66 filers Visit website Investor relations